Skip to main content
Clinical Trials/TCTR20210623004
TCTR20210623004
Recruiting
Phase 2

Postoperative hypofractionation and simultaneous integrated boost with or without regional nodal irradiation by TomoTherapy for breast cancer

/A0 sites48 target enrollmentStarted: June 23, 2021Last updated:

Overview

Phase
Phase 2
Status
Recruiting
Sponsor
/A
Enrollment
48

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to N/A (No limit) (—)
Sex
Female

Inclusion Criteria

  • 1\. Received breast conserving surgery (BCS)
  • 2\. With or without the indication for regional nodal irradiation (RNI)
  • 3\. Pathologically confirmed breast cancer
  • 4\. Free surgical margins from both invasive carcinoma and ductal carcinoma in situ (DCIS)
  • 5\. Indication for tumor bed boost according institutional protocol
  • (age \< 50 years or age \> 50 years with high risk features)
  • 6\. Clearly identified primary tumor region preferably by radiopaque clips
  • 7\. Surgical wound healing without signs of infection
  • 8\. Age 18 years old or more
  • 9\. ECOG performance status 0\-1

Exclusion Criteria

  • 1\. Patients received mastectomy
  • 2\. No indication for boost radiation
  • 3\. Inadequate identification of the boost volume
  • 4\. Bilateral breast cancer
  • 5\. History of prior breast or thoracic radiotherapy
  • 6\. Extended postoperative seroma at the beginning of radiotherapy
  • 7\. Pregnant or lactating patients
  • 8\. Treatment history of other cancer
  • 9\. Patients with serious, uncontrolled, physical or cerebrovascular disorders

Investigators

Sponsor
/A

Similar Trials